Does not affect the quality of life.

‘The results of CONKO-001 shows that adjuvant treatment with gemcitabine in the dose and use minimal toxicity, does not affect the quality of life, and offers a good, and currently perhaps the best chance for prolonged disease – free survival in patients[ certain types of] resection for pancreatic cancer, the authors conclude.

Patients received chemotherapy with gemcitabine or without chemotherapy . Developed with a median follow-up of 4.5 years, recurrent cancer in 74.3 % in the gemcitabine group and 92 % in the control group. The estimated median disease-free survival was 13.4 months in the gemcitabine group compared with 6.9 months in the control group. Estimated disease-free survival at 3 and 5 years was 23.5 % and 16.5 % in the gemcitabine group and 7.5 % and 5.5 % in the control group. There was no difference in overall survival between the gemcitabine group and the control group..Dr Margaret increased risk of renal stone disease result of global warming, UT Southwestern research.

Global warming is likely belt kidney stone of the share of the population kidney stones by expanding of high-risk regional as at known affected increasing neighboring states, researchers on UT Southwestern Medical Center and UT Dallas find.